产品: Glucagon 抗体
货号: AF0166
描述: Rabbit polyclonal antibody to Glucagon
应用: WB IHC IF/ICC
反应: Human, Mouse, Rat, Monkey
预测: Pig, Bovine, Horse, Sheep, Dog, Chicken
分子量: 25kDa; 21kD(Calculated).
蛋白号: P01275
RRID: AB_2833359

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:3000, IF/ICC: 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat,Monkey
预测:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Dog(100%), Chicken(85%)
克隆:
Polyclonal
特异性:
GLP1 Antibody detects endogenous levels of total GLP1.
RRID:
AB_2833359
引用格式: Affinity Biosciences Cat# AF0166, RRID:AB_2833359.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

GCG;glicentin-related polypeptide;GLP-1;GLP-1(7-36);GLP-1(7-37);GLP-2;GLP1;GLP1, included;GLP2;GLP2, included;GLUC_HUMAN;Glucagon;Glucagon like peptide 1;glucagon-like peptide 1;Glucagon-like peptide 1, included;Glucagon-like peptide 2;Glucagon-like peptide 2, included;GRPP;OXM;OXY;preproglucagon;

抗原和靶标

免疫原:
Uniprot:
基因/基因ID:
表达:
P01275 GLUC_HUMAN:

Glucagon is secreted in the A cells of the islets of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP-1 and GLP-2 are also secreted in selected neurons in the brain.

描述:
GCG Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Belongs to the glucagon family. Glucagon release is stimulated by hypoglycemia and inhibited by hyperglycemia, insulin, and somatostatin. GLP-1 and GLP-2 are induced in response to nutrient ingestion.
序列:
MKSIYFVAGLFVMLVQGSWQRSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAKRHDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGRRDFPEEVAIVEELGRRHADGSFSDEMNTILDNLAARDFINWLIQTKITDRK

种属预测

种属预测:

score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Chicken
85
Xenopus
69
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - P01275 作为底物

Site PTM Type Enzyme
T26 Phosphorylation
S32 Phosphorylation
S34 Phosphorylation
S36 Phosphorylation
S42 Phosphorylation
S54 Phosphorylation
Y62 Phosphorylation
S68 Phosphorylation
S150 Phosphorylation
S152 Phosphorylation

研究背景

功能:

Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.

GLP-1 is a potent stimulator of glucose-dependent insulin release. Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis.

GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.

Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.

Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.

翻译修饰:

Proglucagon is post-translationally processed in a tissue-specific manner in pancreatic A cells and intestinal L cells. In pancreatic A cells, the major bioactive hormone is glucagon cleaved by PCSK2/PC2. In the intestinal L cells PCSK1/PC1 liberates GLP-1, GLP-2, glicentin and oxyntomodulin. GLP-1 is further N-terminally truncated by post-translational processing in the intestinal L cells resulting in GLP-1(7-37) GLP-1-(7-36)amide. The C-terminal amidation is neither important for the metabolism of GLP-1 nor for its effects on the endocrine pancreas.

细胞定位:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Glucagon is secreted in the A cells of the islets of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP-1 and GLP-2 are also secreted in selected neurons in the brain.

蛋白家族:

Belongs to the glucagon family.

研究领域

· Organismal Systems > Endocrine system > Insulin secretion.   (View pathway)

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

文献引用

1). Liu W et al. Possible role of GLP-1 in antidepressant effects of metformin and exercise in CUMS mice. JOURNAL OF AFFECTIVE DISORDERS 2018 Dec 26;246:486-497 (PubMed: 30599373) [IF=6.6]

Application: WB    Species: mouse    Sample: hippocampus

Fig. 3. |CUMS reduces protein levels of hippocampal GLP-1 in mice. GLP-1 protein levels in serum (A, n = 8 per group) and hippocampus (B, n = 3–4 per group).Hippocampal GLP-1R distribution (C: top, ventral hippocampus; bottom, dorsal hippocampus), gray value (D) and positive cell number (E) using IHC. Magnification 200 × , Scale bars = 50 μm. N = 3 sections per brain were analyzed, n = 3 per group. Data are presented as means ± SEM. *p < 0.05 versus Con.

2). Mohammed El Tabaa M et al. GLP-1 mediates the neuroprotective action of crocin against cigarette smoking-induced cognitive disorders via suppressing HMGB1-RAGE/TLR4-NF-κB pathway. International Immunopharmacology 2022 Sep;110:108995. (PubMed: 35785730) [IF=5.6]

Application: WB    Species: Rat    Sample:

Fig. 4. Effect of crocin on hippocampal GLP-1 level and expression in a rat model of CS-induced cognitive disorders. (A) GLP-1 level (pg/g tissue); n = 6, (B) western blot showing GLP-1 expression, and (C) bar graph reflecting GLP-1 expression. Protein expression level was normalized to β-actin and shown relative to that of control; n = 3. Values were expressed as means ± SD. Significant difference were presented at *p < 0.05, **p < 0.01, and ***p < 0.001; using One-way ANOVA followed by Tukey's Honestly Significant Difference (HSD) post-hoc. C: control; Cro: crocin; CS: cigarettes smoke; GLP-1: Glucagon-like peptide-1.

3). Li X et al. Intake of flavonoids from Astragalus membranaceus ameliorated brain impairment in diabetic mice via modulating brain-gut axis. Chinese Medicine 2022 Feb 12;17(1):22. (PubMed: 35151348) [IF=4.9]

Application: IHC    Species: Rat    Sample: brain

Fig. 8 The effects of NaB on brain function in STZ induced diabetic mice. A Body weight, and B Fasting blood glucose in mice during the experiment. C Fasting blood glucose decrement at Week 14. D H&E staining of mice brain (black arrow indicates the atrophic and deep staining of neurons; red arrow indicates the loose structure of brain tissues; and the swollen, vacuolar neurons were indicated by green arrow). ELISA assay for concentration of E BDNF in brain tissue, and F AGEs and G IL-1β in serum. H IHC analysis of GABA and I GLP-1 in intestine tissues (red arrow indicates the GLP-1). J Expression of GABA in brain cortex or hippocampus by immunohistochemical analysis. *p < 0.05, **p < 0.01, vs. NC group; #p < 0.05, ##p < 0.01, vs. T2DM group

4). Bai Y et al. The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice. MICROBIAL PATHOGENESIS 2020 Dec 5;150:104645. (PubMed: 33285220) [IF=3.8]

Application: WB    Species: Mice    Sample: lung tissues

Fig. 2. GCG mRNA expression and GCG precursor protein are increased, but total GLP-1 and active GLP-1 levels are decreased in mice during infection. (A) GCG mRNA expression in the lungs of mock and H9N2 groups (n = 5). (B) Representative western blotting bands of the GCG precursor protein in the lungs of mock and H9N2 groups. (C) Data of GCG precursor protein expression in the lungs of mock and H9N2 groups (n = 4). (D) Representative immunohistochemistry images of GCG precursor protein expressed in the lungs of mock and H9N2 groups on 7 d.p.i. The results were similar in five mice of per group. GCG precursor protein positive cells was noted by red arrows. (E) Total GLP-1 in the lungs of mock and H9N2 groups (n = 5). (F) Total GLP-1 in the serum of mock and H9N2 groups (n = 5). (G) Active GLP- 1 in the lungs of mock and H9N2 groups (n = 5). (H) Active GLP-1 in the serum of mock and H9N2 groups (n = 5). (I) Active GLP-1/total GLP-1 in the lungs of mock and H9N2 groups on 5 and 7d.p.i. (n = 5). (J) Active GLP-1/total GLP-1 in the serum of mock and H9N2 groups on 5 and 7d.p.i. (n = 5). Data are presented as mean ± SD, analyzed using Sidak’s or Tukey’s multiple comparisons tests. * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001, NS = non-significant. GCG, glucagon. GLP-1, glucagon like peptide-1. d.p.i., days post infection.

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.